Clinical validation of the 2017 international consensus guidelines on intraductal papillary mucinous neoplasm of the pancreas

• DOI: 10.4174/astr.2019.97.2.58
• Publication Date: 2019-07-30T07:54:26Z
• Authors: Jae Seung Kang; Taesung Park; Youngmin Han; Seungyeon Lee; Heeju Lim; Hyeongseok Kim; Se Hyung Kim; Wooil Kwon; Sun-Whe Kim; Jin-Young Jang
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Original Article; 3. Good health

Purpose: The 2017 international consensus guidelines (ICG) for intraductal papillary mucinous neoplasm (IPMN) of the pancreas were recently released.Important changes included addition worrisome features such as elevated serum CA 19-9 and rapid cyst growth (>5 mm over 2 years).We aimed to clinically validate ICG compare diagnostic performance between 2012 ICG.Methods: This was a retrospective cohort study.During January 2000-January 2017, patients who underwent complete surgical resection had pathologic confirmation branch-duct or mixed-type IPMN included.To evaluate performance, areas under receiver operating curves (AUCs) evaluated.Results: A total 448 included.The presence mural nodule (hazard ratio [HR], 9.12; 95% confidence interval [CI], 4.60-18.09;P = 0.001), main pancreatic duct dilatation mm) (HR, 5.32; CI, 2.67-10.60;P thickened cystic wall 3.40; 1.51-7.63;P 0.003), level (>37 unit/mL) 5.25; 2.05-13.42;P 0.001) significantly associated with malignant IPMN.Malignant lesions showed rate >5 years more frequently than benign (60.9% vs. 29.7%,P 0.012).The AUC higher (0.784 0.746). Conclusion:The new is valid, superior ICG.The inclusion appropriate.